99% Purity CAS 1454846-35-5 Lorlatinib Intermediate Lorlatinib PF 06463922 Powder Lorlatinib

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: Dsung-Lorlatinib
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Product Name: Lorlatinib
• Name: Lorlatinib Powder
• Appearance: White Powder
• Color: White
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Anti-Cancer
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 1454846-35-5
• Einecs No.: 813-704-5
• Mf: C21h19fn6o2
• Boiling Point: 675.0+-55.0 C(Predicted)
• Density: 1.42+-0.1 g/cm3(Predicted)
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-Sung
• Origin: Shaanxi
• Production Capacity: 10kg/Month

Product Description

99% Purity CAS 1454846-35-5 Lorlatinib Intermediate Lorlatinib Pf 06463922 Powder Lorlatinib

 

Product Description

Product Details

Product Name	Lorlatinib
CAS No.	1454846-35-5
Purity	99%
MF	C21H19FN6O2
Appearance and shape	White  powder

Lorlatinib (PF-06463922) is a new drug under development for the sub-group of advanced non-small cell lung cancerwho are ALK or ROS1 positive and have already undergone gene treatment with drugs thatspecifically targetthis type of cancer.Lorlatinib is currently being evaluated in phase II clinical trials as an oral dose at 100 mg daily. If marketed it will becomean additional targeted treatment for this sub-group of ALKor ROS1 positive patients.
Lorlatinib acts by inhibiting the ALK and ROS1 receptor tyrosine kinases, with potent activity against a broad spectrum of ALK resistant mutations. By inhibiting ALK phosphorylation and ROS1 activity, lorlatinib inhibits the downstream signalling, thereby inducing the apoptosis process, which results in the inhibition of tumour cells proliferation.
Due to tumor complexity and development of resistance to treatment, disease progression is a challenge in patients with ALK-positive metastatic non-small cell lung cancer (NSCLC). A common site for progression in metastatic NSCLC is the brain.
Lorlatinib was specifically designed to inhibit tumor mutations that drive resistance to other ALK inhibitors and to penetrate the blood brain barrier.

Application & Function

Lorlatinib should be regarded as a third-generation ALK inhibitor. It can inhibit 9 mutations that are resistant to crizotinib. It has strong blood-brain barrier penetration ability and strong brain entry effect. It is especially suitable for resistance to other ALKs. of patients with advanced NSCLC. Lorlatinib carries EGFR-sensitive mutations in advanced non-small cell lung cancer, which can be treated with Chemicalbook by many EGFR inhibitors, such as the first-generation drugs Iressa, Tarceva, and Chimera, and the second-generation drugs afatinib , Dacomitinib, the third-generation drug osimertinib (AZD9291)-the effective rate of these targeted drugs is as high as 70% or even higher, and the side effects are not too small. They are the first choice for the treatment of such patients.

Specification